Brigham and Women’s Hospital is recruiting people with malignant pleural mesothelioma for a Phase 2 supportive-care trial (MAGIC AKI) testing whether prophylactic intravenous magnesium reduces acute kidney injury during surgery with hyperthermic intraoperative chemotherapy (HIOC).
The trial, designated NCT05730816, is enrolling at Brigham and Women’s Hospital in Massachusetts.
About the Study
This randomized, placebo-controlled Phase 2 study tests whether prophylactic high-dose IV magnesium administration reduces the risk of acute kidney injury (AKI) in people with malignant mesothelioma who receive hyperthermic intraoperative chemotherapy (HIOC) with cisplatin, compared to placebo. The primary endpoint is the area under the curve of serum creatinine measured daily over 7 days after surgery.
Treatment Approach
This is not an immunotherapy trial. It is a supportive-care study evaluating intravenous magnesium as a kidney-protective agent during cisplatin-based HIOC surgery.
Key trial details:
- Phase: Phase 2
- Sponsor: Brigham and Women’s Hospital
- Intervention: Prophylactic high-dose IV magnesium vs. placebo
- Status: Recruiting
Why This Trial Matters
Cisplatin given during hyperthermic intraoperative chemotherapy can damage the kidneys. If prophylactic magnesium lowers the rate of acute kidney injury, it could make HIOC safer for people with mesothelioma who undergo cytoreductive surgery.
Study Locations
The trial is recruiting at:
- Brigham and Women’s Hospital, Massachusetts
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening